SGLT2 Inhibitors: No Benefit in Hospitalized COVID-19 SGLT2 Inhibitors: No Benefit in Hospitalized COVID-19

However, an important take-home message from this new meta-analysis is that these widely used medications appeared to be safe even in acutely ill hospitalized patients, the researchers say.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Cardiology News Source Type: news